1. 1. Cruz-Benedetti, I. C., Bublot, I., Ribas, T., Fourel, I., Vogl, C., Dubois, C., Milani, M., Ida, K. K. and Portier, K. 2018. Pharmacokinetics of intramuscular alfaxalone and its echocardiographic, cardiopulmonary and sedative effects in healthy dogs. PLoS One 13: e204553.
2. 2. Davies, P. 2014. GABAA receptor genetics and clinical pharmacology. Curr. Anesthesiol. Rep. 4: 42–48.
3. 3. Diehl, K. H., Hull, R., Morton, D., Pfister, R., Rabemampianina, Y., Smith, D., Vidal, J. M., van de Vorstenbosch, C., European Federation of Pharmaceutical Industries Association and European Centre for the Validation of Alternative Methods. 2001. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J. Appl. Toxicol. 21: 15–23.
4. 4. Ferré, P. J., Pasloske, K., Whittem, T., Ranasinghe, M. G., Li, Q. and Lefebvre, H. P. 2006. Plasma pharmacokinetics of alfaxalone in dogs after an intravenous bolus of Alfaxan-CD RTU. Vet. Anaesth. Analg. 33: 229–236.
5. 5. Girard, N. M., Leece, E. A., Cardwell, J., Adams, V. J. and Brearley, J. C. 2010. The sedative effects of low-dose medetomidine and butorphanol alone and in combination intravenously in dogs. Vet. Anaesth. Analg. 37: 1–6.